SPTX advances oral neuropsychiatric therapies toward pivotal trials
SPTX is advancing novel neuropsychiatric treatments using the Glyph™ platform to enhance oral bioavailability and safety. Lead candidates for depression and anxiety have shown strong early results, with key data readouts expected through 2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.